DE69900746D1 - Gesteuerte verabreichung von peptiden oder proteinen - Google Patents

Gesteuerte verabreichung von peptiden oder proteinen

Info

Publication number
DE69900746D1
DE69900746D1 DE69900746T DE69900746T DE69900746D1 DE 69900746 D1 DE69900746 D1 DE 69900746D1 DE 69900746 T DE69900746 T DE 69900746T DE 69900746 T DE69900746 T DE 69900746T DE 69900746 D1 DE69900746 D1 DE 69900746D1
Authority
DE
Germany
Prior art keywords
peptides
proteins
controlled administration
administration
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69900746T
Other languages
English (en)
Other versions
DE69900746T2 (de
Inventor
John Wang
Bing Yang
N Jennings
A Protter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Application granted granted Critical
Publication of DE69900746D1 publication Critical patent/DE69900746D1/de
Publication of DE69900746T2 publication Critical patent/DE69900746T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
DE69900746T 1998-01-30 1999-01-28 Gesteuerte verabreichung von peptiden oder proteinen Expired - Lifetime DE69900746T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7317498P 1998-01-30 1998-01-30
PCT/US1999/001967 WO1999038495A2 (en) 1998-01-30 1999-01-28 Controlled release delivery of peptide or protein

Publications (2)

Publication Number Publication Date
DE69900746D1 true DE69900746D1 (de) 2002-02-28
DE69900746T2 DE69900746T2 (de) 2002-08-14

Family

ID=22112175

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69900746T Expired - Lifetime DE69900746T2 (de) 1998-01-30 1999-01-28 Gesteuerte verabreichung von peptiden oder proteinen

Country Status (7)

Country Link
US (1) US6187330B1 (de)
EP (1) EP1051157B1 (de)
JP (3) JP4549529B2 (de)
AU (1) AU2484399A (de)
CA (1) CA2317411C (de)
DE (1) DE69900746T2 (de)
WO (1) WO1999038495A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
TWI283695B (en) * 1999-10-21 2007-07-11 Hayashibara Biochem Lab Thermoplastic shaped-body of trehalose, process and uses thereof
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6702744B2 (en) * 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
ES2415654T3 (es) * 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003234090A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
EP2561887B8 (de) 2003-01-14 2016-12-21 Dana-Farber Cancer Institute, Inc. Sensibilisator für Krebstherapie
US8821473B2 (en) * 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7931693B2 (en) * 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7854944B2 (en) 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US20080125745A1 (en) * 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8303972B2 (en) * 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
DK1973406T3 (da) 2005-12-28 2014-06-23 Advanced Bionutrition Corp Fremføringsmiddel til probiotiske bakerier omfattende en tør blanding af polysaccharider, saccharider, polyoler i glasform
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US9060835B2 (en) * 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US7732190B2 (en) * 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
EP2117354B1 (de) * 2006-12-18 2018-08-08 Advanced BioNutrition Corp. Trockenes nahrungsmittel mit lebendem probiotikum
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20110137227A1 (en) * 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2410996B1 (de) 2009-03-27 2017-08-02 Advanced Bionutrition Corp. Impfstoffe in mikropartikelform zur oralen oder nasalen impfung und stärkung von tieren einschliesslich fischen
SG176253A1 (en) 2009-05-26 2011-12-29 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
WO2011094469A2 (en) 2010-01-28 2011-08-04 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
US8629106B2 (en) * 2010-03-16 2014-01-14 Janssen Biotech, Inc. Affinity peptides toward BMP-2
LT2603100T (lt) 2010-08-13 2018-07-25 Advanced Bionutrition Corp. Stabilizuojanti kompozicija, skirta biologinių medžiagų sausam saugojimui
MX367075B (es) 2011-01-28 2019-08-05 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en metodos de tratamiento de grupos concretos de pacientes.
US8112218B2 (en) * 2011-03-10 2012-02-07 Ford Global Technologies, Llc Method for controlling an engine
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2848201C (en) 2011-09-16 2020-10-27 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
AU2012347926B2 (en) 2011-12-05 2018-03-15 Incept, Llc Medical organogel processes and compositions
JP6195848B2 (ja) 2012-01-27 2017-09-13 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 糖ポリマーを用いた生体分子の安定化
US8822423B2 (en) 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
KR20160024906A (ko) 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
AU2015289613B2 (en) 2014-07-16 2021-07-01 Regeneron Pharmaceuticals, Inc. Methods for treating patients with heterozygous familial hypercholesterolemia (heFH)
WO2016115520A1 (en) 2015-01-16 2016-07-21 The J. David Gladstone Institutes Methods for treating tauopathy
JP6438333B2 (ja) * 2015-03-23 2018-12-12 株式会社日立製作所 移動型ｘ線撮影装置
US10953050B2 (en) 2015-07-29 2021-03-23 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
CN112739366B (zh) * 2018-09-14 2024-08-30 卡拉治疗学股份有限公司 κ阿片受体激动剂的口服配制品
BR112022018654A2 (pt) * 2020-03-18 2023-01-17 Cara Therapeutics Inc Formulações de oligossacarídeo de agonistas do receptor opioide kappa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
CA1334379C (en) * 1987-11-24 1995-02-14 James William Mcginity Method for preparing a solid sustained release form of a functionally active composition
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
DE527942T1 (de) 1990-05-04 1994-03-03 Perio Prod Ltd System zur arzneistoffabgabe im colon.
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
WO1993010758A1 (en) * 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
AU5092493A (en) 1992-09-08 1994-03-29 Allergan, Inc. Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle
EP0773781B1 (de) * 1994-08-04 2003-10-22 Elan Drug Delivery Limited Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
DE69816980T2 (de) * 1997-03-31 2004-07-22 Alza Corp., Palo Alto Implantierbares diffusionabgabesystem

Also Published As

Publication number Publication date
JP5868895B2 (ja) 2016-02-24
JP2002501886A (ja) 2002-01-22
CA2317411C (en) 2005-06-28
DE69900746T2 (de) 2002-08-14
WO1999038495A3 (en) 1999-09-30
JP2013189448A (ja) 2013-09-26
EP1051157A2 (de) 2000-11-15
US6187330B1 (en) 2001-02-13
CA2317411A1 (en) 1999-08-05
EP1051157B1 (de) 2002-01-02
WO1999038495A2 (en) 1999-08-05
AU2484399A (en) 1999-08-16
JP2009286803A (ja) 2009-12-10
JP4549529B2 (ja) 2010-09-22

Similar Documents

Publication Publication Date Title
DE69900746D1 (de) Gesteuerte verabreichung von peptiden oder proteinen
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
NO983364L (no) Konsensusproteiner
DE69434520D1 (de) Biotinylierung von proteinen
DK0981375T3 (da) Farmaceutiske præparater indeholdende plasmaprotein
DE4393381T1 (de) Peptide
DE69934380D1 (de) Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung
DE69526801D1 (de) Aerosolformulierungen mit peptiden und proteinen
DK91192D0 (da) Protein
DE3685626D1 (de) Sequenzierung von peptiden.
DK6893D0 (da) Peptid
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
DE69132708D1 (de) Therapeutische Vervendung von Peptiden mit Thrombospondin - ähnlicher Aktivität
DE69810761D1 (de) Synergistische mischungen von ausgewählten aminosäuren
NO20000575D0 (no) Rekombinant ekspresjon av insulin C-peptid
DE69123345D1 (de) Sequenzielle c-termin degradierung von peptiden und proteinen
ATE283706T1 (de) ßGEGEN RACEMISIERUNG STABILISIERTE PHARMAZEUTISCHE ZUBEREITUNGEN VON CILANSETRONß
ID21034A (id) Protein kinase dan penggunaannya
BR9606951A (pt) Proteinas matantes
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
NO980375D0 (no) Humant MP52 Arg protein
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
EE200000694A (et) Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon
KR960010685A (ko) 펩티드 및 그 용도

Legal Events

Date Code Title Description
8364 No opposition during term of opposition